All In Biotech

Drug Trial Radar · NCT06355609

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

A Perspective Observation Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib Plus Anlotinib in EGFR-Sensitive Mutations Combined With Co-Mutations Locally Advanced or Metastatic NSCLC

Last checked: Nov 20, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 1, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Hunan Province Tumor HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive non-small cell lung cancer.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • sunvozertinib in combination with AnlotinibDrug

    Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily (QD in Day 1-14),21 days in one cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.